All market verdicts

MRNA DOWN market verdict | Ezbrisk

Published: 1785537704048

Anomaly score: 0.0

Confidence: 0.78

Market summary

Moderna Trial Delay

Ezbrisk assessment

The company surpassed revenue and earnings expectations while lowering its expense outlook, yet news of a clinical trial delay for a key vaccine candidate is weighing on the share price.

Sources: https://www.modernatx.com/en-us/investors/financials/quarterly-results

Verdict ID: fae1edde-76d2-4f5d-bd68-0d27e9594f45